HROWHARROW, INC.

Nasdaq harrowinc.com


$ 41.49 $ 0.31 (0.75 %)    

Wednesday, 11-Sep-2024 15:59:57 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 41.37
$ 41.35 x 100
$ 41.51 x 100
-- - --
$ 7.60 - $ 44.80
310,640
na
1.47B
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-19-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-08-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-13-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-14-2017 09-30-2017 10-Q
29 08-10-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-21-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-23-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-13-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 b-riley-securities-reiterates-buy-on-harrow-maintains-50-price-target

B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $50 price target.

 b-riley-securities-maintains-buy-on-harrow-raises-price-target-to-50

B. Riley Securities analyst Sahil Kazmi maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $29 to $50.

 craig-hallum-maintains-buy-on-harrow-raises-price-target-to-45

Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $30 to $45.

 harrow-q2-2024-adj-eps-006-beats-020-estimate-sales-48939m-beat-42509m-estimate

Harrow (NASDAQ:HROW) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.20) by 70 ...

 harrow-enters-into-340b-prime-vendor-program-contract-with-apexus

Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has ...

 craig-hallum-maintains-buy-on-harrow-raises-price-target-to-30

Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $30.

Core News & Articles
Market-Moving News for June 20th
06/20/2024 12:17:43

HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale...

 melt-pharmaceuticals-reports-first-patient-dosed-in-phase-3-program-of-its-melt-300-for-needle--and-opioid-free-sedation-in-patients-undergoing-cataract-surgery-topline-readout-expected-in-q4-2024

Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural...

 harrows-vevye-shows-results-for-dry-eye-disease-in-essence-2-study

Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑...

 lake-street-maintains-buy-on-harrow-raises-price-target-to-25

Lake Street analyst Brooks O'Neil maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $20 to $25.

 craig-hallum-maintains-buy-on-harrow-raises-price-target-to-26

Craig-Hallum maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $24 to $26.

 b-riley-securities-reiterates-buy-on-harrow-raises-price-target-to-29

B. Riley Securities analyst Sahil Kazmi reiterates Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $29.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION